Clinical Trials

A Phase 3, Multicenter, Randomized, Open Label Study To Compare The Efficacy And Safety Of Bb2121 Versus Standard Triplet Regimens In Subjects With Relapsed And Refractory Multiple Myeloma (Rrmm) (Karmma-3)


Study ID
Celgene bb2121-MM-003 (KarMMa-3)

NCT Number
NCT03651128 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0684

Principle Investigator
Dr. David Siegel

Phase
III

Sponsor
Celgene


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now